dailypolitical.com
Positivewww.dailypolitical.com ·
Q2 Eps Estimates for Sutro Biopharma Lifted by Hc Wainwright
Nutritional ProgramsFood And In Kind TransfersTherapeuticSocial Assistance
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article covers analyst EPS estimate revisions for Sutro Biopharma (NASDAQ:STRO), a biotech company. No direct commercial mechanism (e.g., product launch, supply chain event, regulatory change) is reported. The impact is limited to equity valuation sentiment; no operational or margin channel is identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- HC Wainwright raised Q2 2026 EPS estimate from ($2.58) to ($2.33) for Sutro Biopharma.
- Consensus full-year EPS estimate is ($9.04) per share.
- Wells Fargo increased price target from $8.00 to $27.00.
- Deutsche Bank raised price target from $51.00 to $55.00.
- Sutro Biopharma reported Q1 revenue of $14.52M, beating consensus of $8.89M.
No mid-term commercial impact on Sutro Biopharma; operational mechanisms absent.
Sign in to see all sector verdicts, full thesis and counter-argument debate.
Sector impact at a glance
- PHARMA_BIOTECHmid